MaxCyte, Inc. (LON:MXCT – Get Free Report) shares reached a new 52-week low during mid-day trading on Monday . The company traded as low as GBX 260 ($3.35) and last traded at GBX 270 ($3.47), with a volume of 54707 shares trading hands. The stock had previously closed at GBX 275 ($3.54).
MaxCyte Trading Down 1.8 %
The company has a quick ratio of 14.38, a current ratio of 14.31 and a debt-to-equity ratio of 8.37. The stock has a market cap of £283.74 million, a price-to-earnings ratio of -1,038.46 and a beta of 1.13. The business has a 50-day moving average of GBX 290.68 and a 200-day moving average of GBX 323.82.
Insider Buying and Selling
In related news, insider Stan Erck sold 47,689 shares of the company’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of GBX 388 ($4.99), for a total value of £185,033.32 ($238,107.48). 1.45% of the stock is owned by corporate insiders.
MaxCyte Company Profile
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Featured Stories
- Five stocks we like better than MaxCyte
- 3 Warren Buffett Stocks to Buy Now
- Rocket Lab is the Right Stock for the Right Time
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Best Stocks Under $5.00
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.